Agile Therapeutics (NASDAQ:AGRX) has been given a $4.00 price target by investment analysts at HC Wainwright in a report released on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 479.71% from the company’s current price.
A number of other brokerages also recently weighed in on AGRX. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, March 14th. ValuEngine upgraded Agile Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Agile Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.00.
Shares of AGRX stock opened at $0.69 on Monday. The company has a market capitalization of $23.63 million, a price-to-earnings ratio of -0.76 and a beta of 2.12. Agile Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $5.60.
Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its stake in Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 20,654 shares during the period. A.R.T. Advisors LLC grew its stake in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares during the period. Dimensional Fund Advisors LP grew its stake in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares during the period. Broadfin Capital LLC acquired a new stake in Agile Therapeutics in the fourth quarter valued at approximately $964,000. Finally, Renaissance Technologies LLC grew its stake in Agile Therapeutics by 313.7% in the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after acquiring an additional 277,600 shares during the period. 72.15% of the stock is owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.